Pharmacotherapy for smoking cessation: present and future.

Area of Science:

• Pharmacology
• Addiction Medicine
• Public Health

Background:

• Tobacco dependence is a chronic condition requiring persistent treatment.
• Current FDA-approved cessation aids include nicotine replacement therapy, bupropion, and varenicline.
• These medications are recommended for most smokers, but data for pregnant women and adolescents is limited.

Purpose of the Study:

• To review the efficacy and safety of current smoking cessation pharmacotherapies.
• To identify potential second-line and novel pharmacotherapeutic agents for tobacco dependence.
• To emphasize the importance of offering pharmacotherapy alongside counseling for all quit attempts.

Main Methods:

• Literature review of FDA-approved smoking cessation medications.
• Discussion of established first-line treatments and their limitations.
• Exploration of second-line agents (clonidine, nortriptyline) and emerging drug candidates.

Main Results:

• First-line pharmacotherapies demonstrate broad efficacy but have benefit-risk uncertainties in specific groups.
• Relapse rates indicate a need for additional treatment options.
• Clonidine and nortriptyline are identified as potential second-line interventions.

Conclusions:

• Clinicians should offer counseling and pharmacotherapy to all patients attempting to quit smoking.
• Existing first-line medications are effective, but not universally sufficient.
• Development of novel pharmacotherapies is crucial to improve long-term smoking cessation success rates.